Rigel, MD Anderson partner to expand REZLIDHIA assessment in AML
AML is a fast-developing cancer originating in the blood and bone marrow, impacting myeloid cells that typically transform into different types of mature blood cells. REZLIDHIA is a
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Kyverna Therapeutics’ chimeric antigen receptor (CAR) T-cell product candidate, KYV-101 for treating refractory stiff-person syndrome (SPS).
The new, first-in-class inhibitor is being assessed to treat a range of immune-mediated disorders, including lupus nephritis (LN), the most common secondary immune-mediated glomerular disease. Following the acceptance,